Pharmacopeia (PCOP) Surges On Positive DARA Phase 2a Trial Data
More News related to PCOP
- Pharmacopeia Announces Further Reductions to Workforce
- Pharmacopeia (PCOP) Reports Q2 Loss of $0.53, Misses by 10c
- Pharmacopeia Announces Second Quarter 2008 Financial Results
- Pharmacopeia to Present At the Canaccord Adams 28th Annual Global Growth Conference
- Pharmacopeia Earns Milestone Payment From Wyeth
More News related to FDA
- Celgene (CELG) Down On Talk of REVLIMID Warning
- Orthofix International (OFIX) Receives FDA 510(k) Approval
- Rosetta Genomics (ROSG) Identifies Potential microRNA Biomarkers in Blood Serum
- BioCryst Pharma (BCRX) Reports Results From BCX-4208 Phase IIa Trial in Subjects With Psoriasis
- Celgene (CELG) Granted FDA Fast Track Designation for Amrubicin
Shares of Pharmacopeia (Nasdaq: PCOP) are 33% higher in pre-open trading today after the company announced that PS433540, its first-in-class Dual Acting Receptor Antagonist (DARA), showed statistically significant blood pressure reductions in a Phase 2a study in patients with mild to moderate hypertension.
The Phase 2a study met its primary endpoint by showing a statistically significant reduction in mean 24-hour systolic ambulatory blood pressure over placebo. The study also showed statistically significant improvements over placebo in mean 24-hour diastolic ambulatory blood pressure as well as seated blood pressure.
Great Call from Canaccord Adams on this one!
Related Categories
FDAMomentum Movers
Stocks Mentioned
-0.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
